About the Journal
Aims and scope of journal
The Pharmacogenomics Journal is a print and electronic journal, which is dedicated to the rapid publication of original research on pharmacogenomics and its clinical applications.
Key areas of coverage include:
- Effects of genetic variability on drug toxicity and efficacy
- Identification and functional characterization of polymorphisms relevant to drug action
- Integration of new developments in the genome project and proteomics into clinical medicine, pharmacology, and therapeutics
- Clinical implementation of pharmacogenomics
- Identification of novel genomic targets for drug development
- Economics of genome-guided interventions
- ELSI issues on the clinical implementation of pharmacogenomics
- Pharmacogenomics in developing countries
- Companion diagnostics and drug development
The 2019 peer review performance metrics for The Pharmacogenomics Journal are shown below:
Average time to decision without external review - 25 days
Average time to decision following external review - 183 days
Average time from acceptance to publication - 11 days
Article page views - 186,379
Altmetric mentions - 601
The 2019 journal metrics* for The Pharmacogenomics Journal are as follows:
2-year Impact Factor: 2.910
5-year Impact Factor: 3.018
Immediacy index: 1.421
Eigenfactor® score: 0.00452
Article influence score: 0.910
Current Contents/Thomson Reuters
University of Toronto
ISSN and eISSN
The international standard serial number (ISSN) for The Pharmacogenomics Journal is 1470-269X, and the electronic international standard serial number (eISSN) is 1473-1150.
The Pharmacogenomics Journal now provides its latest table of contents as an RSS web feed. This allows users with an RSS reader to receive automatic updates whenever new content is added to these pages.
Find out more about RSS feeds, how to download an RSS reader and see all the news feeds offered by Springer Nature.